目的 探究通心络胶囊联合艾司洛尔治疗冠心病心肌缺血的临床疗效。方法 选取保定市252医院2012年10月—2015年10月收治的冠心病心肌缺血患者100例，随机分为对照组（50例）和治疗组（50例）。两组均给予基础治疗，对照组iv盐酸艾司洛尔注射液，负荷量0.5 mg/(kg·min)，持续1 min。随后静脉点滴维持量0.05 mg/(kg·min)，4 min后若疗效理想则继续维持，若疗效不佳可重复给予负荷量并维持量以0.05 mg/(kg·min)的幅度递增。治疗组在对照组的基础上口服通心络胶囊，3粒/次，3次/d，两组均连续治疗2周。治疗后，比较两组的临床疗效、心率、血压和血脂的变化情况。结果 治疗后，对照组和治疗组总有效率分别为84.00%和94.00%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组的心率、血压和血脂明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些指标的下降幅度优于对照组，两组比较差异有统计学意义（P<0.05）。结论 通心络胶囊联合艾司洛尔治疗冠心病心肌缺血具有较好的临床疗效，可明显改善患者的心率、血压和血脂，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Tongxinluo Capsules combined with esmolol in treatment of coronary heart disease with myocardial ischemia. Methods Patients (100 cases) with coronary heart disease with myocardial ischemia in No. 252 Hospital of Baoding from October 2012 to October 2015 were randomly divided into control (50 cases) and treatment (50 cases) groups. All patients were given basic treatment. Patients in the control group were iv administered with Esmolol Hydrochloride Injection, with the load of 0.5 mg/(kg·min) continuing for 1 min. Then they were administered with Esmolol Hydrochloride Injection for iv drip, maintained the dosage of 0.05 mg/(kg·min). After 4 min, maintain the dosage if the clinical efficacy was ideal, or give the load of 0.5 mg/(kg·min) repeatedly and gradually added the maintained dosage at the amplitude of 0.05 mg/(kg·min). The patients in the treatment group were po administered with Tongxinluo Capsules on the basis of control group, 3 grains/time, three times daily. The patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy, changes of heart rate, blood pressure, and blood lipid in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment group were 84.00% and 94.00%, respectively, and there were differences between two groups (P<0.05). After treatment, heart rate, blood pressure, and blood lipid in two groups were lower than those before treatment with significant difference (P<0.05). And these indexes in the treatment group were lower than those in the control group, and the difference was significant (P<0.05). Conclusion Tongxinluo Capsules combined with esmolol has clinical curative effect in treatment of coronary heart disease with myocardial ischemia, and can significantly improve the heart rate, blood pressure, and blood lipid, which has a certain clinical application.